Quest Diagnostics Incorporated DGX SPX
Company Overview
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Why Investors Should Care
Trades at a P/E of 22.7, below the sector median of 25.4.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $11.04B (+11.8% YoY); net profit $992.00M.
- Trailing 12 Months Year-on-year growth — revenue +9.2%, earnings +15.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.8%, profit CAGR 6.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.81% |
| 1 Year: | 9.20% |
Compounded Profit Growth
| 5 Years: | 6.13% |
| 1 Year: | 15.50% |
Stock Price Performance
| 1 Year: | +24.50% |
| 6 Months: | +19.63% |
| 3 Months: | +7.22% |
| 1 Month: | +1.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.90 · Neutral
P/E of 22.74 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DGX Quest Diagnostics Incorporated SPX | 206.00 | 22.74 | $22.80B | 1.69% | 11.16% | 14.54% | 2.81% | 6.13% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 1.88B | 1.92B | 1.89B | 1.84B | 1.89B | 1.95B | 1.96B | 1.93B | 1.82B | 1.83B | 2.79B | 3.00B | 2.72B | 2.55B | 2.77B | 2.61B | 2.45B | 2.49B | 2.33B | 2.34B | 2.29B | 2.37B | 2.40B | 2.49B | 2.65B | 2.76B | 2.82B | 2.90B |
| Gross Profit | 676.00M | 743.00M | 718.00M | 699.00M | 719.00M | 751.00M | 728.00M | 701.00M | 652.00M | 694.00M | 666.00M | 671.00M | 658.00M | 676.00M | 667.00M | 604.00M | 647.00M | 688.00M | 692.00M | 662.00M | 552.00M | 606.00M | 1.21B | 1.27B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 228.00M | 301.00M | 631.00M | - | 257.00M | 422.00M | 322.00M | - | 279.00M | 319.00M | 298.00M | - | 272.00M | 305.00M | 304.00M | - | 248.00M | 307.00M | 313.00M | - | 175.00M | 283.00M | 718.00M | - | 660.00M | 533.00M | 652.00M | 513.00M | 388.00M | 392.00M | 305.00M | 348.00M | 342.00M | 300.00M | 355.00M | 330.00M | 346.00M | 438.00M | 386.00M | 399.00M |
| Net Income | 61.00M | 118.00M | 342.00M | 188.00M | 103.00M | 195.00M | 192.00M | 155.00M | 164.00M | 193.00M | 161.00M | 254.00M | 177.00M | 219.00M | 213.00M | 127.00M | 164.00M | 226.00M | 215.00M | 253.00M | 99.00M | 185.00M | 568.00M | 579.00M | 469.00M | 631.00M | 505.00M | 355.00M | 234.00M | 256.00M | 202.00M | 235.00M | 225.00M | 194.00M | 229.00M | 226.00M | 220.00M | 282.00M | 245.00M | 252.00M |
| Diluted EPS | 0.42 | 0.81 | 2.35 | 1.29 | 0.71 | 1.37 | 1.34 | 1.09 | 1.16 | 1.37 | 1.15 | 1.82 | 1.27 | 1.57 | 1.53 | 0.92 | 1.20 | 1.66 | 1.56 | 1.86 | 0.73 | 1.36 | 4.14 | 4.21 | 3.46 | 4.96 | 4.02 | 2.92 | 1.96 | 2.17 | 1.78 | 2.05 | 1.96 | 1.72 | 2.03 | 1.99 | 1.94 | 2.47 | 2.16 | 2.24 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.70B | 7.25B | 7.46B | 7.26B | 7.39B | 7.38B | 7.15B | 7.43B | 7.49B | 7.21B | 7.40B | 7.53B | 7.73B | 9.44B | 10.79B | 9.88B | 9.25B | 9.87B | 11.04B |
| Gross Profit | - | - | 3.13B | 3.05B | 3.03B | 3.02B | 2.82B | 2.80B | 2.84B | 2.90B | 2.68B | 2.60B | 2.69B | 3.63B | - | - | - | - | - |
| Operating Income | 1.09B | 1.22B | 1.36B | 1.28B | 987.00M | 1.20B | 1.48B | 983.00M | 1.40B | 1.28B | 1.17B | 1.10B | 1.23B | 1.97B | 2.38B | 1.43B | 1.26B | 1.35B | 1.56B |
| Net Income | 339.94M | 581.49M | 729.11M | 720.89M | 471.00M | 556.00M | 849.00M | 556.00M | 709.00M | 645.00M | 772.00M | 736.00M | 858.00M | 1.43B | 2.00B | 946.00M | 854.00M | 871.00M | 992.00M |
| Diluted EPS | 1.74 | 2.96 | 3.87 | 4.05 | 2.92 | 3.46 | 5.54 | 3.81 | 4.87 | 4.51 | 5.50 | 5.29 | 6.28 | 10.47 | 15.55 | 7.97 | 7.49 | 7.69 | 8.75 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 8.40B | 8.56B | 8.53B | 9.31B | 9.28B | 8.95B | 9.86B | 9.96B | 10.10B | 10.50B | 11.00B | 12.84B | 14.03B | 13.61B | 12.84B | 14.02B | 16.15B | 16.23B |
| Total Equity | 3.04B | 3.35B | 3.60B | 3.99B | 4.03B | 3.69B | 4.16B | 3.95B | 4.30B | 4.68B | 4.63B | 4.92B | 5.22B | 5.64B | 6.76B | 6.44B | 5.89B | 6.31B | 6.78B | 7.17B |
| Cash & Equivalents | 149.64M | 167.59M | 253.95M | 534.26M | 449.00M | 165.00M | 296.00M | 187.00M | 192.00M | 133.00M | 359.00M | 137.00M | 135.00M | 1.19B | 1.16B | 872.00M | 315.00M | 686.00M | 549.00M | 420.00M |
| Long Term Debt | - | - | - | - | 2.64B | 3.94B | 3.36B | 3.12B | 3.22B | 3.49B | 3.73B | 3.75B | 3.43B | 3.97B | 4.01B | 4.01B | 3.98B | 4.41B | 5.62B | 5.17B |
| Current Liabilities | - | - | 1.22B | 1.06B | 1.21B | 1.56B | 1.05B | 1.13B | 1.71B | 1.17B | 981.00M | 1.06B | 1.49B | 1.99B | 1.78B | 1.75B | 1.55B | 1.81B | 2.17B | 2.28B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 926.92M | 1.06B | 997.42M | 1.12B | 895.00M | 1.19B | 652.00M | 944.00M | 821.00M | 1.12B | 1.18B | 1.20B | 1.24B | 2.00B | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B |
| Investing Cash Flow | -1.76B | -198.88M | -195.90M | -216.51M | -1.24B | -217.00M | 328.00M | -1.02B | -362.00M | -127.00M | -830.00M | -801.00M | -411.00M | -772.00M | 21.00M | -543.00M | -1.06B | -2.55B | -631.00M |
| Financing Cash Flow | 850.22M | -777.81M | -521.20M | -986.49M | 64.00M | -822.00M | -1.11B | 86.00M | -518.00M | -738.00M | -592.00M | -401.00M | 225.00M | -1.27B | -2.54B | -1.73B | 160.00M | 1.08B | -1.39B |
| Capital Expenditure | -219.10M | -212.68M | -166.93M | -205.40M | -161.00M | -182.00M | -231.00M | -308.00M | -263.00M | -293.00M | -252.00M | -383.00M | -400.00M | -418.00M | -403.00M | -404.00M | -408.00M | -425.00M | -527.00M |
| Free Cash Flow | 707.82M | 850.37M | 830.49M | 912.65M | 734.00M | 1.00B | 421.00M | 636.00M | 558.00M | 823.00M | 923.00M | 817.00M | 843.00M | 1.59B | 1.83B | 1.31B | 864.00M | 909.00M | 1.36B |
| Share Buybacks | 145.66M | 254.00M | 499.99M | 750.00M | 935.00M | 200.00M | 1.04B | 132.00M | 224.00M | 590.00M | 465.00M | 322.00M | 353.00M | 325.00M | 2.20B | 1.41B | 275.00M | 151.00M | 450.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 42.0% | 42.0% | 41.0% | 40.9% | 39.5% | 37.6% | 37.8% | 40.2% | 36.2% | 34.6% | 34.8% | 38.5% | - | - | - | - | - |
| Operating Margin % | 16.3% | 16.9% | 18.2% | 17.7% | 13.4% | 16.3% | 20.6% | 13.2% | 18.7% | 17.7% | 15.7% | 14.6% | 15.9% | 20.9% | 22.1% | 14.4% | 13.6% | 13.6% | 14.1% |
| Net Margin % | 5.1% | 8.0% | 9.8% | 9.9% | 6.4% | 7.5% | 11.9% | 7.5% | 9.5% | 8.9% | 10.4% | 9.8% | 11.1% | 15.2% | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
| ROE % | 10.2% | 16.1% | 18.3% | 17.9% | 12.8% | 13.4% | 21.5% | 12.9% | 15.1% | 13.9% | 15.7% | 14.1% | 15.2% | 21.2% | 31.0% | 16.1% | 13.5% | 12.9% | 13.8% |
| ROCE % | - | 17.0% | 18.1% | 17.6% | 12.7% | 14.6% | 18.9% | 12.1% | 15.9% | 14.0% | 12.3% | 11.6% | 11.3% | 16.1% | 20.1% | 12.7% | 10.3% | 9.6% | 11.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.29% | 9.17M | $1.97B |
| 2 | Vanguard Capital Management LLC | 6.46% | 7.15M | $1.53B |
| 3 | Price (T.Rowe) Associates Inc | 5.69% | 6.30M | $1.35B |
| 4 | Vanguard Portfolio Management LLC | 5.49% | 6.08M | $1.30B |
| 5 | State Street Corporation | 4.86% | 5.38M | $1.15B |
| 6 | Boston Partners | 3.62% | 4.01M | $860.82M |
| 7 | JPMORGAN CHASE & CO | 3.47% | 3.85M | $825.26M |
| 8 | Geode Capital Management, LLC | 2.79% | 3.09M | $662.17M |
| 9 | Morgan Stanley | 2.24% | 2.48M | $532.02M |
| 10 | Edgepoint Investment Group Inc. | 2.03% | 2.24M | $481.42M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DGX
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus - TradingView
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPQXZ5MWJ2LURDVkllaE1DaGxnSjNuMklpbVRPV1ZsQkgxSnZ1Tm9OSVJvY0g0V2c2VWlTSUxqa0ppTmxLb0dBaDdlajEzUzZCMFFFMVdCSTUwMlRfbEFPQVlyemY4dGtBTVdIQmZMaHhRUjFha09MS3JuWGhTa3oyY1lWWnUwbmswNlhvbF…
Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability - ChartMill
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQT29RaTA1YV8wM2NmMGdkOXVOSEJPRGxRcENXOXJWMjBZWWtXaU1WOHBzZHJveXNsTEtaYU51OWdvbmtqT1FHOEkyekxNX09oOEVHM3ZkRkpfaGFaMVJ0WjdTazlfd3NyMHhCa1Iyc0MtTEdQT25MSjk4S0lwS2dpc3llVVhUMVliOGFYUm…
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPeWpRY2VOUDN4N3JWcHQtTE1MLVJRTzhSYjJaOVZDS2otXzJGR0lUd1NFNW5aYVRRSWZoS0N6NkVVOWhqRkgzQ3NObHRDN054RVE1dkt6TlhqT2tDOHpMRGpmTTFiQl9GZDVDM0RBVE5PenNLWTBVa05GZ0g1NExRVjFKeVc0cG14Y3RHcn…
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxOVDlMbTZKd01Wckd0b3RpU2p1SHMyZ19scGlKRDg1YzdGYTB0N0FWd3FLdGFsLTRfWlc3bDhFc3ktRXh3VW90Zy1rWm9nVlhpbnpQbHJxQkNYaU9wT1djbWdTQ3VUQWx0UVBhRk16WWpldnp4azlPMjVqWkk2TEpmTEtaMEJlZHBXbmdUSH…
DGX Maintained by Baird -- Price Target Raised to $236 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNUm4wUVFvRTRQS0s1aUJRRXpRT1lwT1RlMjMyek5yMWRMOWRfTkszaENlU0xtbFMwem9zWktBRWJDamZvcDdqakVUTHpieExGSm56NHFSQXdmdDJyWE8xd2tIWDBNRkFtdjk0Q1pCSnY5UURzQUFWWjJrQXVUSE5vN3JxaVE4OG1SanFxSz…
Quest Diagnostics (DGX) Stock Trades Cheap On Cash Flow But Fair On Earnings - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxOM092SmtTbW51OHJBaHRISnRkRGZhNVNiTzl3VkNjOElHODZFcmRuQlphaW1FWVMtRWZZaDZuSE9TTDl2Q2RNZTI5d2hnSTNHcWFUVWNvQTRhWTEyTVJUS2tEWVhrSk5IT3BxbWctVGNFcHRQRy1tdUZSUmhPZDRQcjE0U0s2blVQTDJZN2…
DGX — Frequently Asked Questions
What is the current share price of Quest Diagnostics Incorporated (DGX)?
As of 2026-07-14 21:23 PDT, Quest Diagnostics Incorporated (DGX) trades at $206.00 on NYSE. Its 52-week range is $163.55 to $215.15.
What is the market capitalisation of DGX?
Quest Diagnostics Incorporated (DGX) has a market capitalisation of $22.80B on NYSE.
What is the P/E ratio of DGX?
DGX trades at a trailing price-to-earnings (P/E) ratio of 22.74. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.06.
Does DGX pay a dividend?
Quest Diagnostics Incorporated (DGX) currently offers a dividend yield of 1.69%.
What is the return on equity (ROE) of DGX?
DGX has a return on equity (ROE) of 14.54%. Its return on capital employed (ROCE) is 11.16%.
Is DGX a good stock to buy?
This page provides a data-driven analysis of Quest Diagnostics Incorporated (DGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.